Floatz logo

Silymarin

Non-alcoholic Steatohepatitis

Madaus IncPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

131 Active assets in the Non-alcoholic Steatohepatitis cohort.

Asset / SponsorPhaseRating
Resmetirom
City University of New York
Phase 4BBB
Pentoxifylline
Al-Azhar University
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB
Semaglutide
Cascade Pharmaceuticals, Inc
Phase 4BBB
Firsocostat
Gilead Sciences
Phase 2BBB

View all 50 →

Same molecule, other indications

Silymarin is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative ·
69 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
63 / 100
View asset →
peripheral neuropathyDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →